Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline

Jefferies analyst Thomas Wei reiterated a Buy rating and $50 price target on Stemline Therapeutics (NASDAQ: STML) saying an aanalysis of oncology orphan drugs suggests upside to the SL-401 timeline.

Wei commented, "We reviewed data on all 89 approved orphan oncology drugs since 1999. Half (45) were approved on single-arm trials with the smallest filing based on 18 patients. The median overall response rate was 37% in these single-arm trials. With SL-401 response rates higher than all but two examples, we see accelerated prospects for SL-401 in rare lymphomas, with the potential for 12 months of upside to our 2H17 approval estimate."

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $14.99 yesterday.

You May Also Be Interested In

• MSC Industrial (MSM) PT Raised to $130 at Jefferies
• Jefferies on Meta Platforms Inc. (META): 'We are bullish'
• SLB (SLB) PT Lowered to $62 at TD Cowen